Urologic Oncology Archives
Study finds Mark Cuban’s Cost Plus Drug Company could save taxpayers millions on Medicare generic oncology drugs
Jun. 8, 2023—Vanderbilt research finds that the U.S. government could save taxpayers between $228 million-$2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban Cost Plus Drug Company.
More U.S. prostate cancer patients choosing active surveillance
Apr. 3, 2023—A Vanderbilt study found the number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with favorable intermediate-risk cancers.
Donation leads to lectureship for Urologic Oncology
Aug. 17, 2022—A generous donation is leading to the Hassell Franklin Lectureship for the Division of Urologic Oncology at Vanderbilt University Medical Center.
Davis named senior medical director for VICC Cancer Care Network and Strategy
Aug. 6, 2020—Nancy Davis, MD, has been named senior medical director for VICC Cancer Care Network and Strategy, a new leadership position at Vanderbilt-Ingram Cancer Center responsible for expanding cancer clinics within and beyond the Middle Tennessee catchment area.
New Physician Spotlight: Niels Johnsen
Aug. 26, 2019—Niels Johnsen, MD, has joined the Vanderbilt University Medical Center Department of Urology after completing his residency at VUMC. He began seeing patients Aug. 1.
Tool guides decision-making for prostate cancer patients
Mar. 28, 2019—Prostate cancer patients in Nashville and Los Angeles are benefiting from a computer-based decision aid that implements the latest study results to tailor treatment options to an individual’s quality-of-life priorities.
Prostate cancer screening recommendations altered for some older men
Apr. 20, 2017—A federal task force has changed its recommendation about prostate cancer screening for some older men. The United States Preventive Services Task Force (USPSTF) now recommends that men between the ages of 55 to 69 consult with their physicians about getting routine screening blood tests to detect prostate cancer.
Study shows statin use improves renal cell cancer survival
Apr. 16, 2015—A new study led by Vanderbilt University investigators found that patients being treated with statins at the time of surgery for kidney cancer, also known as renal cell carcinoma, had improved overall survival and disease-specific survival.
Urologic cancer studies point to need for referral education
May. 22, 2014—Women with blood in their urine (hematuria) were less than half as likely as men with the same issue to be referred to a urologist for further tests, according to a new VUMC study.